"Any physical activity I pay for the next day, and my body just flares, and it's very disappointing because I love to dance.

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

The cutting-edge technology used in COVID-19 shots may lead to new treatments for other diseases. But some conservatives are ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

Scientists say that officials from the National Institutes of Health urged them to remove references to mRNA vaccine technology ...

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft sales ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

Five years ago, on March 11, the World Health Organization declared COVID-19 a global pandemic. The vaccines “underwent the most intensive safety analysis in U.S. history." ...

The pandemic's volatility affected all public companies, but some saw their business deeply transformed. Here's how three of ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

It has been five years since the World Health Organisation (WHO) declared COVID-19 a pandemic in March 2020 a decision that ...